Related Experiment Video
Updated: May 29, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast
Ho Jun Seol1, Juyoun Jin, Dong-Ho Seong
1Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract:
Neural stem cells (NSCs) led to the development of a novel strategy for delivering therapeutic genes to tumors. NSCs expressing rabbit carboxyl esterase (F3.CE), which activates CPT-11, significantly inhibited the growth of MDA-MB-435 cells in the presence of CPT-11. F3.CE cells migrated selectively into the brain metastases located in the opposite hemisphere. The treatment also significantly decreased tumor volume in immune-deficient mice bearing MDA-MB-435 tumors when F3.CE cells were transplanted into the contralateral hemisphere. The survival rate was significantly prolonged with the treatment with F3.CE and CPT-11. This strategy may be considered as an effective treatment regimen for brain metastases.
Insights
Neural stem cells (NSCs) engineered to express a gene-activating enzyme (F3.CE) effectively targeted brain metastases. This novel therapy, combined with CPT-11, significantly reduced tumor growth and prolonged survival in mice.
Area of Science:
- Oncology
- Gene Therapy
- Neuroscience
Background:
- Brain metastases pose a significant therapeutic challenge.
- Developing targeted drug delivery systems for brain tumors is crucial.
- Neural stem cells (NSCs) offer potential for tumor-homing and drug delivery.
Purpose of the Study:
- To evaluate the efficacy of genetically modified NSCs for treating brain metastases.
- To assess the tumor-selective delivery and therapeutic potential of NSCs expressing rabbit carboxyl esterase (F3.CE).
- To determine the impact of F3.CE-expressing NSCs combined with CPT-11 on tumor growth and survival.
Main Methods:
- NSCs were engineered to express rabbit carboxyl esterase (F3.CE) to activate the chemotherapy drug CPT-11.
- MDA-MB-435 tumor cells were used to establish brain metastases in immune-deficient mice.
- F3.CE-expressing NSCs were transplanted into the contralateral hemisphere of tumor-bearing mice.
- Tumor volume, cell migration, and survival rates were monitored.
Main Results:
- F3.CE-expressing NSCs selectively migrated to brain metastases.
- The combination of F3.CE NSCs and CPT-11 significantly inhibited MDA-MB-435 tumor cell growth.
- Transplantation of F3.CE NSCs into the contralateral hemisphere significantly decreased tumor volume.
- Treatment with F3.CE NSCs and CPT-11 significantly prolonged survival rates.
Conclusions:
- Genetically engineered NSCs represent a promising strategy for targeted gene delivery to brain metastases.
- This novel approach, utilizing F3.CE-expressing NSCs and CPT-11, demonstrates significant therapeutic potential for brain metastases.
- The findings suggest this treatment regimen could be effective for managing brain metastases.
